Can a Nimble FDA Help Your Portfolio ETFs?
November 19, 2020 at 05:00 AM EST
The Food and Drug Administration (FDA) appears likely to be active on the drug review front in the months, with COVID-19 in the way. Expect that activity could benefit exchange traded funds with exposure to small- and mid-cap biotechnology stocks, including the ALPS Medical Breakthroughs ETF ( SBIO ).